Literature DB >> 7749162

Parity is associated with axillary nodal involvement in operable breast cancer.

R K Orr1, K M Fraher.   

Abstract

INTRODUCTION: Although multiparous women have a decreased incidence of breast cancer, several series have observed that multiparous women have a higher risk of axillary nodal metastases and diminished survival.
METHODS: To study this hypothesis in greater detail, this study analyzed data from 223 consecutive women with clinically operable (T1-3, N0-1, M0) breast cancer, all of whom had undergone axillary node dissection (AND) by one surgeon (83 mastectomy/AND, 140 lumpectomy/AND). The number of pregnancies and other hormonally related factors were recorded. Results were compared to pathologic data (node status, tumor size, estrogen and progesterone receptors).
RESULTS: Seventy-eight patients (35.0%) had positive axillary nodes. Increasing parity was associated with an increased likelihood of positive nodes (Odds ratio 1.22 (95% CI: 1.04-1.42), p = 0.012) as was increasing tumor size (Odds ratio 1.31 (1.07-1.59), p = 0.007). The effect of parity was independent of tumor size, age, or hormone receptors.
CONCLUSIONS: In this series, which includes only operatively staged patients, increasing parity is associated with nodal positivity. This effect is of a magnitude similar to that of increasing tumor size, and confirms observations from other studies. Information regarding parity may be useful for prognostic purposes, as well as providing insights into basic breast cancer biology.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7749162     DOI: 10.1007/BF00666493

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  21 in total

1.  Risk factors and 10-year breast cancer survival in northern Alberta.

Authors:  A W Lees; H J Jenkins; C L May; G Cherian; E W Lam; J Hanson
Journal:  Breast Cancer Res Treat       Date:  1989-03       Impact factor: 4.872

2.  Combined effect of childbearing, menstrual events, and body size on age-specific breast cancer risk.

Authors:  J B Kampert; A S Whittemore; R S Paffenbarger
Journal:  Am J Epidemiol       Date:  1988-11       Impact factor: 4.897

3.  Estrogen and progesterone receptors in breast cancer patients. Epidemiologic characteristics and survival differences.

Authors:  A M Ruder; F Lubin; Y Wax; A Geier; E Alfundary; A Chetrit
Journal:  Cancer       Date:  1989-07-01       Impact factor: 6.860

4.  Body size, reproductive factors, and breast cancer survival.

Authors:  J C Mohle-Boetani; S Grosser; A S Whittemore; M Malec; J B Kampert; R S Paffenbarger
Journal:  Prev Med       Date:  1988-09       Impact factor: 4.018

5.  Prognostic factors in breast cancer.

Authors:  M K Palmer; J P Lythgoe; A Smith
Journal:  Br J Surg       Date:  1982-12       Impact factor: 6.939

6.  Short term increase in risk of breast cancer after full term pregnancy.

Authors:  P Bruzzi; E Negri; C La Vecchia; A Decarli; D Palli; F Parazzini; M R Del Turco
Journal:  BMJ       Date:  1988-10-29

Review 7.  Differentiation of the mammary gland and susceptibility to carcinogenesis.

Authors:  J Russo; L K Tay; I H Russo
Journal:  Breast Cancer Res Treat       Date:  1982       Impact factor: 4.872

8.  Elevated levels of prolactin in nulliparous women.

Authors:  M C Yu; V R Gerkins; B E Henderson; J B Brown; M C Pike
Journal:  Br J Cancer       Date:  1981-06       Impact factor: 7.640

9.  Breast cancer estrogen and progesterone receptors: associations with patients' clinical and epidemiologic characteristics. G.I.V.I.O. (Interdisciplinary Group for Cancer Care Evaluation), Italy.

Authors: 
Journal:  Tumori       Date:  1991-12-31

10.  Risk factors for breast cancer by oestrogen receptor status: a population-based case-control study.

Authors:  J A Cooper; T E Rohan; E L Cant; D J Horsfall; W D Tilley
Journal:  Br J Cancer       Date:  1989-01       Impact factor: 7.640

View more
  1 in total

1.  Parity, age at first childbirth and the prognosis of primary breast cancer.

Authors:  N Kroman; J Wohlfahrt; K W Andersen; H T Mouridsen; T Westergaard; M Melbye
Journal:  Br J Cancer       Date:  1998-12       Impact factor: 7.640

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.